Venous thromboembolism - null regimens

Back to Top
The purpose of this page is to provide references to "null therapy" such as placebo and observation. These references provide further insight into the historical development of the treatment landscape. See the main VTE page for regimens that include active treatment.
=VTE primary prophylaxis=
==Observation==
===Regimen===
Study 	Dates of enrollment 	Evidence 	Comparator	Comparative Efficacy
O'Brien et al. 2023 (PREVAPIX-ALL)	2015-10-22 to 2021-06-04	Phase 3 (C)	Apixaban 	Did not meet primary endpoint of composite of symptomatic or clinically unsuspected venous thromboembolism
No treatment.
===References===
#PREVAPIX-ALL: O'Brien SH, Rodriguez V, Lew G, Newburger JW, Schultz CL, Orgel E, Derr K, Ranalli MA, Esbenshade AJ, Hochberg J, Kang HJ, Dinikina Y, Mills D, Donovan M, Dyme JL, Favatella NA, Mitchell LG; PREVAPIX-ALL investigators. Apixaban versus no anticoagulation for the prevention of venous thromboembolism in children with newly diagnosed acute lymphoblastic leukaemia or lymphoma (PREVAPIX-ALL): a phase 3, open-label, randomised, controlled trial. Lancet Haematol. 2024 Jan;11(1):e27-e37. Epub 2023 Nov 16. link to original article EuroPMC NCT02369653
==Placebo==
===Regimen===
Study 	Dates of enrollment	Evidence 	Comparator 	Comparative Efficacy
Gärdlund et al. 1996 	1988-1991 	Phase 3 (C)	UFH; SC 	Did not meet primary endpoint of necropsy-verified pulmonary embolism of predefined clinical relevance
Hull et al. 2010 (EXCLAIM) 	2002-02 to 2006-03 	Phase 3 (C)	Enoxaparin 	Higher composite VTE rate
Kakkar et al. 2011 (LIFENOX) 	2008-01 to 2010-09 	Phase 3 (C)	Enoxaparin 	Did not meet primary endpoint of death rate at 30 days
Spyropoulos et al. 2018 (MARINER)	2014-06 to 2018-01 	Phase 3 (C)	Rivaroxaban	Did not meet primary endpoint of symptomatic VTE or death due to VTE
Khorana et al. 2019 (CASSINI) 	Not reported 	Phase 3 (C)	Rivaroxaban	Did not meet primary endpoint of objectively confirmed proximal DVT in a lower limb, PE, symptomatic DVT in an upper limb or distal DVT in a lower limb, and death from VTE up to 180 days
Mottier et al. 2023 (SYMPTOMS) 	2015-09 to 2020-09 	Phase 3 (C)	Enoxaparin 	Did not meet primary endpoint of symptomatic VTE at 30 days
No active treatment.
===References===
#Gärdlund B; Heparin Prophylaxis Study Group. Randomised, controlled trial of low-dose heparin for prevention of fatal pulmonary embolism in patients with infectious diseases. Lancet. 1996 May 18;347(9012):1357-61. link to original article EuroPMC
#EXCLAIM: Hull RD, Schellong SM, Tapson VF, Monreal M, Samama MM, Nicol P, Vicaut E, Turpie AG, Yusen RD; EXCLAIM (Extended Prophylaxis for Venous ThromboEmbolism in Acutely Ill Medical Patients With Prolonged Immobilization) study. Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial. Ann Intern Med. 2010 Jul 6;153(1):8-18. link to original article EuroPMC NCT00077753
#LIFENOX: Kakkar AK, Cimminiello C, Goldhaber SZ, Parakh R, Wang C, Bergmann JF; LIFENOX Investigators. Low-molecular-weight heparin and mortality in acutely ill medical patients. N Engl J Med. 2011 Dec 29;365(26):2463-72. link to original article EuroPMC NCT00622648
#MARINER: Spyropoulos AC, Ageno W, Albers GW, Elliott CG, Halperin JL, Hiatt WR, Maynard GA, Steg PG, Weitz JI, Suh E, Spiro TE, Barnathan ES, Raskob GE; MARINER Investigators. Rivaroxaban for thromboprophylaxis after hospitalization for medical illness. N Engl J Med. 2018 Sep 20;379(12):1118-1127. Epub 2018 Aug 26. link to original article EuroPMC NCT02111564
#CASSINI: Khorana AA, Soff GA, Kakkar AK, Vadhan-Raj S, Riess H, Wun T, Streiff MB, Garcia DA, Liebman HA, Belani CP, O'Reilly EM, Patel JN, Yimer HA, Wildgoose P, Burton P, Vijapurkar U, Kaul S, Eikelboom J, McBane R, Bauer KA, Kuderer NM, Lyman GH; CASSINI Investigators. Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer. N Engl J Med. 2019 Feb 21;380(8):720-728. link to original article EuroPMC NCT02555878
#SYMPTOMS: Mottier D, Girard P, Couturaud F, Lacut K, Le Moigne E, Paleiron N, Guellec D, Sanchez O, Cogulet V, Laporte S, Marhic G, Mismetti P, Presles E, Robert-Ebadi H, Mahé I, Plaisance L, Reny JL, Darbellay Farhoumand P, Cuvelier C, Le Henaff C, Lambert Y, Danguy Des Deserts M, Rousseau Legrand C, Boutreux S, Bleher Y, Decours R, Trinh-Duc A, Armengol G, Benhamou Y, Daumas A, Guyot SL, De Carvalho H, Lamia B, Righini M, Meyer G, Le Gal G. Enoxaparin versus Placebo to Prevent Symptomatic Venous Thromboembolism in Hospitalized Older Adult Medical Patients. NEJM Evid. 2023 Aug;2(8):EVIDoa2200332. Epub 2023 Jun 27. link to original article EuroPMC NCT02379806
Category:Venous thromboembolism regimens
Category:Disease-specific pages
Category:Thrombotic disorders
Category:Null regimens